Form 8-K bluebird bio, Inc. For: Mar 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
bluebird bio (BLUE) PT Raised to $35 at BMO Capital
March 29, 2021 6:40 AM EDTBMO Capital analyst Matthew Luchini raised the price target on bluebird bio (NASDAQ: BLUE) to $35.00 (from $31.00) while maintaining a Market Perform rating.
The analyst commented, "FDA approved Abecma (bb2121/ide-cel) for relapse/refractory multiple myeloma, in line with its March 27... More
